Gulseren Seven

Gulseren Seven

Auto-generated profile, based on publicly available information

Gulseren Seven

Department of Gastroenterology, Bezmialem University School of Medicine, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GSGulseren Seven
Gulseren Seven
Gokhan SILAHTAROGLUGokhan SILAHTAROGLU
Gokhan SILAHTAROGLU
KKKoray Kochan
Koray Kochan
AIAli Tuzun Ince
Ali Tuzun Ince
DADilek Sema Arici
Dilek Sema Arici
HSHakan Sentürk
Hakan Sentürk

1 June 2011 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
GSGulseren Seven
Gulseren Seven
SKSenem Ceren Karatayli
Senem Ceren Karatayli
SKS. Kenan Kose
S. Kenan Kose
MYMustafa Yakut
Mustafa Yakut
GKGokhan Kabacam
Gokhan Kabacam
DSDetlef Schuppan
Detlef Schuppan
Turkjgastroenterol, Turkgastro

30 December 2022 in Pancreatology
Verified
Journal Article
Closed access
AİAli Tüzün İnce
Ali Tüzün İnce
Gokhan SILAHTAROGLUGokhan SILAHTAROGLU
Gokhan SILAHTAROGLU
GSGülseren Seven
Gülseren Seven
KKKoray Koçhan
Koray Koçhan
KYKemal Yıldız
Kemal Yıldız
HŞHakan Şentürk
Hakan Şentürk

1 March 2025 in Endoscopic Ultrasound
Verified
Journal Article
Open access
SKSERCAN KİREMİTÇİ
SERCAN KİREMİTÇİ
GSGulseren Seven
Gulseren Seven
Gokhan SILAHTAROGLUGokhan SILAHTAROGLU
Gokhan SILAHTAROGLU
KKKoray Kochan
Koray Kochan
STSerife Degirmencioglu Tosun
Serife Degirmencioglu Tosun
HSHakan Senturk
Hakan Senturk
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) are relatively rare and consist of 2% of the all pancreatic tumors. Although some of pNETs have a benign, nonprogressive course, some may be progressive and result with metastasis. We aimed to estimate the grade of pNETs by using artificial intelligence (AI) via deep learning (DL) algorithms as indexing to cyto/histopathological classification according to the World Health Organization 2017. Methods: A total of 803 EUS images were collected from 44 patients who had a cyto/histo-pathologically confirmed diagnosis with EUS fine-needle aspiration or biopsy (FNA/B). First, raw EUS images were prepared for processing by AI via DL algorithms, and convolutional neural networks were utilized to train the machine to predict the grades from EUS images. IBM SPSS 25.0 program was used for statistical analyses. Results: Thirty of the 44 patients (68%) were female, with a median age of 61 (range, 16–80) years. pNETs were mostly located in the pancreatic head: 24 cases (55%). Location was the neck in 3 (7%), body in 10 (22%), and tail in 7 (16%) patients. According to EUS-FNA/B results, 27 patients were grade 1 (G1) (61%); 12, grade 2 (G2) (27%); and 5, grade 3 (G3) (12%). In reference to the performance of AI for predicting the pathological grade, sensitivity was 94.29%; specificity, 97.14%; and accuracy, 96.19%. When the patient groups were subanalyzed as G1, G2, and G3 by the AI model to predict the pathological grade, the accuracy was as follows: for G1, 93.15%; for G2, 91.61%; and for G3, 98.05%. Conclusions: This pilot study suggests that pNET grade prediction can be reliably done on EUS images using AI-based technology.

1 December 2011 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
GSGulseren Seven
Gulseren Seven
KCKubilay Cinar
Kubilay Cinar
MYMustafa Yakut
Mustafa Yakut
RIRamazan Idilman
Ramazan Idilman
AOAli Ozden
Ali Ozden
Owing to its high efficacy, ease of use, perfect adaptation and low complication profile, it is suggested that the triple therapy combination consisting of levofloxacin, amoxicillin and proton pump inhibitor may be an alternative for the first-line and second-line treatment of Helicobacter pylori. The aim of this study is to evaluate the efficacy of the triple therapy regimen containing two different doses of levofloxacin in the first-line eradication treatment. 110 naïve patients with anti Helicobacter pylori treatment indications according to Maastricht III Consensus Report were included to the study. Patients were randomized into two groups as the patients treated with a levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) combination for 10 days (Group 1, n=60) and patients treated with a levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) combination for 10 days (Group 2, n=50). Eradication rate was assessed at the 6th week of therapy just subsequent to termination of treatment. 110 treatment-naïve patients (60 female, mean age: 44.1±14.7 years) were randomized and all patients completed the study. Helicobacter pylori eradication of the Group 1 was 60% and in Group 2 was 72.7%. The difference between the two groups was not statistically significant (p=0.427). None of patients experienced severe complication that would lead to discontinuation of therapy. It is observed that the efficacy of the triple therapy combination containing levofloxacin is not within acceptable limits for the first-line Helicobacter pylori eradication.

4 May 2022 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
GSGulseren Seven
Gulseren Seven
GMGunel Musayeva
Gunel Musayeva
OSOzden Ozluk Seven
Ozden Ozluk Seven
EHEmre Herdan
Emre Herdan
AİAli Tüzün İnce
Ali Tüzün İnce
HSHakan Sentürk
Hakan Sentürk